RedHill Biopharma secures $60m licensing agreement with Hyloris for global commercialization of RHB-102

RedHill Biopharma Ltd. has entered into an exclusive licensing agreement with Hyloris Pharmaceuticals SA, granting the Belgian company the rights to develop and commercialize RHB-102 worldwide, excluding North America. As part of the deal, RedHill will receive an upfront payment along with potential milestone payments of up to $60 million, in addition to mid-20s percent […]